Ascentage Pharma presents positive results for lisaftoclax in myeloid malignancies at ASCO 2025

From GlobeNewswire: 2025-06-02 19:30:00

Ascentage Pharma presented data from a Phase Ib/II study of lisaftoclax in combination with azacitidine for myeloid malignancies at the ASCO Annual Meeting. The study showed promising antitumor activity and tolerability, including responses in venetoclax-refractory patients. Lisaftoclax, a Bcl-2 inhibitor, is being evaluated in Phase III trials for CLL/SLL, AML, and MDS. The drug has shown potential to overcome venetoclax resistance. Ascentage Pharma is dedicated to addressing unmet medical needs in cancers globally. The company’s lead assets include olverembatinib and lisaftoclax, targeting key proteins in the apoptotic pathway.

The Phase 1b/2 study of lisaftoclax combined with azacitidine in patients with myeloid malignancies demonstrated promising antitumor activity and manageable tolerability. Results showed overall response rates in patients with AML, MDS, and venetoclax-refractory patients. Lisaftoclax has the potential to overcome drug resistance and improve treatment outcomes. Ascentage Pharma is committed to advancing clinical programs to bring novel therapeutics to patients worldwide. The company has a rich pipeline of innovative drug candidates and is conducting global Phase III trials for various indications.



Read more at GlobeNewswire: Live from ASCO 2025 | Ascentage Pharma Presents Clinical